Keyphrases
Mouse Model
100%
Amyotrophic Lateral Sclerosis
100%
Protective Effect
100%
Population-based
100%
Lovastatin
100%
Motor Neuron Disease
85%
Prolonged Survival
28%
Motor Neuron
28%
SOD1G93A Mice
28%
Sulfasalazine
28%
Telmisartan
28%
Microgliosis
14%
Disease Case
14%
Large Population
14%
Relative Risk
14%
Risk Reduction
14%
Screening Approach
14%
Human Dose
14%
Pharmacy Claims
14%
Histological Study
14%
Delayed Onset
14%
Dose-response Relationship
14%
Medicare Beneficiaries
14%
Symptom Onset
14%
Ventral Horn
14%
Population-based Case-control Study
14%
Spinal Motor Neurons
14%
Gait
14%
Osmotic Pump
14%
Neuroprotective Therapy
14%
Dose Equivalent
14%
Comprehensive Screening
14%
US Medicare
14%
Active Ingredients
14%
Delayed Symptoms
14%
Medical Association
14%
Misfolded SOD1
14%
Pharmacology, Toxicology and Pharmaceutical Science
Mouse Model
100%
Amyotrophic Lateral Sclerosis
100%
Mevinolin
100%
Mouse
71%
Motor Neuron Disease
71%
Sulfasalazine
28%
Telmisartan
28%
Symptom
14%
Case-Control Study
14%
Weakness
14%
Neuroprotective Agent
14%
Gliosis
14%